Allogene Therapeutics (ALLO) Other Accumulated Expenses (2018 - 2025)

Allogene Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $2.4 million in Q4 2025.

• Quarterly Other Accumulated Expenses rose 123.6% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 123.6% YoY) and the FY2025 annual result came in at $2.4 million, up 123.6% from the prior year.
• Other Accumulated Expenses climbed to $2.4 million in Q4 2025 per ALLO's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.4 million in Q4 2025 and troughed at $1.1 million in Q4 2024.
• A 5-year average of $1.8 million and a median of $1.8 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2025: Other Accumulated Expenses sank 63.58% in 2021, then jumped 123.6% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $1.7 million in 2021, then climbed by 21.38% to $2.1 million in 2022, then fell by 14.59% to $1.8 million in 2023, then plunged by 40.74% to $1.1 million in 2024, then surged by 123.6% to $2.4 million in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.4 million, $1.1 million, and $1.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.